Sanchez Ramiro

CIK 00018303263 companiesBOSTON, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001830326

Recent Transactions

28 trades

Award
Rapport Therapeutics, Inc.$RAPP
Stock Option (Right to Buy)
2026-06-10+15,200→ 15,200 total
Award
Alto Neuroscience, Inc.$ANRO
Stock Option (right to buy)
2026-05-12+10,958→ 10,958 total
Award
Alto Neuroscience, Inc.$ANRO
Stock Option (right to buy)
2026-01-02$11.82/sh+3,806→ 3,806 total
Award
Alto Neuroscience, Inc.$ANRO
Stock Option (right to buy)
2025-08-12$2.21/sh+3,928→ 3,928 total
Award
Alto Neuroscience, Inc.$ANRO
Stock Option (right to buy)
2025-08-12+30,574→ 30,574 total
Award
Rapport Therapeutics, Inc.$RAPP
Stock Option (Right to Buy)
2025-06-17+10,925→ 10,925 total
Award
Rapport Therapeutics, Inc.$RAPP
Stock Option (Right to Buy)
2024-11-07+29,756→ 29,756 total
Disposition to Issuer
Cerevel Therapeutics Holdings, Inc.
Restricted Stock Units
2024-08-01−87,573→ 0 total
Disposition to Issuer
Cerevel Therapeutics Holdings, Inc.
Stock Option (Right to Buy)
2024-08-01−1,393,153→ 0 total
Disposition to Issuer
Cerevel Therapeutics Holdings, Inc.
Common Stock
2024-08-01−14,673→ 0 total
Award
Cerevel Therapeutics Holdings, Inc.
Restricted Stock Units
2024-01-19+87,573→ 87,573 total
Exercise/Conversion
Cerevel Therapeutics Holdings, Inc.
Common Stock
2023-12-26$3.50/sh+10,000→ 24,673 total
Exercise/Conversion
Cerevel Therapeutics Holdings, Inc.
Stock Option (Right to Buy)
2023-12-26−10,000→ 538,435 total
Sale
Cerevel Therapeutics Holdings, Inc.
Common Stock
2023-12-26$42.47/sh−10,000→ 14,673 total
Sale
Cerevel Therapeutics Holdings, Inc.
Common Stock
2023-12-20$41.42/sh−10,152→ 14,673 total
Exercise/Conversion
Cerevel Therapeutics Holdings, Inc.
Restricted Stock Units
2023-12-19−24,825→ 0 total
Exercise/Conversion
Cerevel Therapeutics Holdings, Inc.
Common Stock
2023-12-19+24,825→ 24,825 total
Exercise/Conversion
Cerevel Therapeutics Holdings, Inc.
Common Stock
2023-12-15$9.88/sh+7,500→ 7,500 total
Exercise/Conversion
Cerevel Therapeutics Holdings, Inc.
Stock Option (Right to Buy)
2023-12-15−7,500→ 123,390 total
Sale
Cerevel Therapeutics Holdings, Inc.
Common Stock
2023-12-15$41.39/sh−7,500→ 0 total
Exercise/Conversion
Cerevel Therapeutics Holdings, Inc.
Stock Option (Right to Buy)
2023-12-07−10,000→ 548,435 total
Sale
Cerevel Therapeutics Holdings, Inc.
Common Stock
2023-12-07$41.37/sh−10,000→ 0 total
Exercise/Conversion
Cerevel Therapeutics Holdings, Inc.
Common Stock
2023-12-07$3.50/sh+10,000→ 10,000 total
Award
Cerevel Therapeutics Holdings, Inc.
Stock Option (Right to Buy)
2023-02-06+97,691→ 97,691 total
Award
Cerevel Therapeutics Holdings, Inc.
Restricted Stock Units
2023-02-06+24,825→ 24,825 total
Award
Cerevel Therapeutics Holdings, Inc.
Stock Option (Right to Buy)
2022-02-09+168,856→ 168,856 total
Award
Cerevel Therapeutics Holdings, Inc.
Stock Option (Right to Buy)
2021-02-03+278,637→ 278,637 total
Award
Cerevel Therapeutics Holdings, Inc.
Stock Option (Right to Buy)
2020-10-28+130,890→ 130,890 total

Companies

Recent Filings

Address

RAPPORT THERAPEUTICS, INC. 99 HIGH STREET, SUITE 2100

BOSTON, MA, 02110

View on SEC.gov